"Human Metapneumovirus causes high morbidity in the population, especially in infants and the elderly." The severity of this virus is the second cause of childhood pneumonia. Our team has developed a safe and effective vaccine against this virus. This has shown excellent protection results in pre-clinical studies.We are currently carrying out the clinical studies necessary to bring this vaccine onto the market and reduce the impact of this disease in the Chilean and international population." 

Research Line / Vaccines
Project:
Safe and effective vaccines against Human Metapneumovirus (hMPV)

Allowing immunization of the population - especially infants and the elderly - against human Metapneumovirus through a recombinant formulation.

The project seeks to develop a genetic test to determine the aggressiveness of thyroid cancer.

"Diagnostic tests only detect viruses, they do not detect bacteria, nor do they report on the severity of inflammatory response and the severity of infection. All of this along with the high costs of current testing creates the challenge and opportunity to develop one test that detects the multiple infectious agents in the respiratory tract in a specific, sensitive and simultaneous way and that detects some gravity and prognosis parameters of the patient so the doctor may decide on the best treatment option.”

Research / Diagnostic Line
Project:
Immunological Tools to Detect Respiratory Pathogens

Inmunologist, BMRC Consortium researcher and Director for Coronovac Study for Chile, said that the collaboration that has happened within Chilean scientist sector "has been very positive and this is a unprecedented event in the science history".

"The development of this project has allowed us to generate a multidisciplinary knowledge platform in order to collaborate in solving the problem of the increasing incidence of metabolic diseases in our population and at a global level."

Research / Therapy Line
Project:
Development of new drugs for the treatment of hypertension and metabolic syndrome

Dr. Hernán González, BMRC Consortium researcher, indetified a frequent issue among its patients and start to investigate until he created a diagnosis technique with a huge potential in his area. Tha was the easy part. Building a medical technology company, valued at US$35 millions (and growing), it could be a little bit harder.